SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: George Mc Geary who wrote (965)7/19/2000 4:13:57 PM
From: BostonView  Read Replies (1) of 1321
 
QLT PhotoTherapeutics (QLTI: news, msgs) shares are up 19 percent on heavy volume. Visudyne was approved for inclusion in U.S. Pharmacopeia for reimbursement through the Healthcare Financing Administration as a drug. Visudyne, co-developed with CIBA Vision, is a treatment for the wet form of age-related macular degeneration, an eye disease responsible for the majority of blindness in people over the
age of 50. Dain Rauscher Wessels analyst David A. Therkelsen said formalized Medicare policies should be forthcoming in several weeks and that this is an important step for the company. He also pointed out, though, that the payment levels are still up in the air.

Cheers!

BV
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News